JAK Inhibitor

JAK Inhibitors (237):

Cat. No.	Nombre del producto	Efecto	Pureza

HY-144075

JAK-IN-19	Inhibitor
JAK-IN-19 is a potent JAK inhibitor (PBMC IFNγ pIC₅₀=7.2 and HLF Eotaxin pIC₅₀=7.7). JAK-IN-19 has good retentive properties in the lung via mitigating being metabolized by Aldehyde Oxidase (AO), with diminished VEGFR2 selectivity (VEGFR2 pIC₅₀=7.0, Aurora B pIC₅₀=5.8).

HY-149284

JAK/HDAC-IN-3	Inhibitor
JAK/HDAC-IN-3 (13a) is a dual JAK and HDAC inhibitor, with IC₅₀ values of 25.36 nM, 0.2 μM and 0.43 μM for JAK2, HDAC and HDAC1, respectively.

HY-RS07022

Jak3 Mouse Pre-designed siRNA Set A	Inhibitor
Jak3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Jak3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-176479

JAK2-IN-12	Inhibitor
JAK2-IN-12 (compound 23) is a JAK2 inhibitor with a pIC₅₀ of 8.2. JAK2-IN-12 can be used for study of myelofibrosi.

HY-153702

JAK-IN-27	Inhibitor
JAK-IN-27 (compound 1) is an orally active and potent JAKS family kinase inhibitor with IC₅₀s of 3.0 nM (TYK2), 7.7 nM (JAK1), 629.6 nM (JAK3), respectively. JAK-IN-27 inhibits IFN-α2B-induced phosphorylation of STAT3 in Jurkat cells (IC₅₀=23.7 nM).

HY-15728S

Radotinib-d₆	Inhibitor
Radotinib-d₆ is deuterium labeled Radotinib (HY-15728). Radotinib (IY-5511) is an orally active and BBB-permeable selective tyrosine kinase Bcr-Abl1 inhibitor with an IC₅₀ of 34 nM. Radotinib has anti-prion and anti-tumor activities. Radotinib can inhibit the proliferation, induce cell cycle arrest and apoptosis of tumor cells . Radotinib can be used in the research of cancer such as chronic myeloid leukemia and multiple myeloma, as well as neurodegenerative diseases such as prion diseases.

HY-144087

TYK2-IN-11	Inhibitor
TYK2-IN-11 (Compound 5B) is a selective Tyk-2 inhibitor with IC₅₀s of 0.016 and 0.31 nM for TYK2-JH2 and JAK1-JH2, respectively. TYK2-IN-11 can be used for the research of inflammatory or autoimmune disease.

HY-155808

STAT3-IN-18	Inhibitor
STAT3-IN-18 (compound SPP) is a platinum (IV) complex with an axial ligand derived from sandalwood. STAT3-IN-18 inhibits the JAK2-STAT3 pathway in breast cancer (BC) cells, with anti-proliferative activity. STAT3-IN-18 activates caspase-3 and increases cleaved polyADP-ribose polymerase to induce apoptosis. STAT3-IN-18 promotes maturation and antigen presentation of dendritic cells and demonstrates safety in vivo.

HY-10409S

Fedratinib-d₉	Inhibitor
Fedratinib-d₉ (TG-101348-d₉) is deuterium labeled Fedratinib. Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC₅₀s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib induces cancer cell apoptosis and has the potential for myeloproliferative disorders research.

HY-169184

GDC-9918	Inhibitor
GDC-9918 (compund GDC-9918) is a Janus kinase inhibitor.

HY-143719

JAK3/BTK-IN-4	Inhibitor
JAK3/BTK-IN-4 is a potent inhibitor of JAK3/BTK. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-4 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147953A1, compound 003)

HY-154969

JAK-IN-29	Inhibitor
JAK-IN-29 (compound 3) is a potent JAK inhibitor.

HY-145029

SYK/JAK-IN-1	Inhibitor
SYK/JAK-IN-1 is a dual Syk/Jak2 kinase inhibitor. SYK/JAK-IN-1 is applicable to cancer-related research.

HY-N1405R

Cucurbitacin I (Standard)	Inhibitor
Cucurbitacin I (Standard) is the analytical standard of Cucurbitacin I. This product is intended for research and analytical applications. Cucurbitacin I is a natural selective inhibitor of JAK2/STAT3, with potent anti-cancer activity.

HY-162030

MMT3-72	Inhibitor
MMT3-72 is a weak inhibitor of JAK1. MMT3-72 has superior efficacy and reduced p-STAT3 in DSS-induced colitis.

HY-118084

LS-104	Inhibitor
LS-104 (Tyrene CR-4) is a non-ATP-competitive kinase inhibitor against JAK2, Bcr-Abl and FLT3. LS-104 potently induces apoptosis in JAK2V617F-positive cells and inhibits JAK2 autophosphorylation and downstream signal transduction. LS-104 also inhibits proliferation and induces potent cytotoxic effects in FLT3 expressing leukemic cells. LS-104 is a hydroxystyryl-acrylonitrile compound, which is promising for research of myeloproliferative disorders and refractory/relapsed hematologic malignancies.

HY-16641

JAK1-IN-17	Inhibitor
JAK1-IN-17 (Compound 31) is a highly selective inhibitor of JAK1 with a K_i of 1.9 nM. JAK1-IN-17 exhibits a low whole blood shift, which allows maintaining good whole blood potency. JAK1-IN-17 is also a nitrile-containing analogue with consistent, yet weak reversible inhibition of CYP3A4 using a midazolam probe (IC₅₀ = 7.9 μM). JAK1-IN-17 can be studied in cancer research.

HY-156535

JAK kinase-IN-1	Inhibitor
JAK kinase-IN-1 (Example 1) is a JAK inhibitor. JAK kinase-IN-1 inhibits TYK2, JAK1, JAK2 and JAK3 with IC₅₀ values of 4.2 nM, 32 nM, 27 nM, 3473 nM respectively.

HY-149718

Antitumor agent-123	Inhibitor
Antitumor agent-123 (Copmound 4d) effectively inhibits multiple kinase targets with anti-cancer effects, including JAK2, JAK3, HDAC1 and HDAC6, with IC₅₀ values of 34.6 and 2.6 μM for JAK2 and JAK3, respectively. Antitumor agent-123 exhibits moderate activity in solid tumor models.

HY-166594S

Deucravacitinib-¹³C,d₃	Inhibitor
Deucravacitinib-¹³C,d₃ is the ¹³C- and deuterium labeled Deucravacitinib. Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable allosteric TYK2 inhibitor for the treatment of autoimmune diseases, which selectively binds to TYK2 pseudokinase (JH2) domain (IC₅₀=1.0 nM) and blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain. Deucravacitinib inhibits IL-12/23 and type I IFN pathways. Deucravacitinib, the FDA's world first de novo deuterium, is available for study in moderate to severe plaque psoriasis.

Name
E-mail *

	Sorry, but the email address you supplied was invalid.